Key result
Cerebral embolic protection devices during TAVR lack efficacy or safety data in protocol-only meta-analysis.
Why the study?
The clinical benefit of cerebral embolic protection devices during transcatheter aortic valve replacement remains uncertain.
Do cerebral embolic protection devices reduce mortality, MACCE, or stroke in patients undergoing TAVR?
Meta-Analysis (n=11,876)
Do cerebral embolic protection devices reduce mortality, MACCE, or stroke in patients undergoing TAVR?
A meta-analysis of 9 RCTs found that routine use of cerebral embolic protection devices during TAVR does not significantly reduce mortality, MACCE, or stroke.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
No data from this protocol-only meta-analysis guide CEP use in TAVR; leaves efficacy and safety unresolved.
INTRODUCTION: Transcatheter aortic valve replacement (TAVR) is an established treatment for severe aortic stenosis but carries a risk of stroke and cerebral embolism. Cerebral embolic protection devices (CEPD), including filter-based and deflection-based systems (Sentinel and TriGUARD), aim to reduce embolic complications; however, their clinical benefit remains uncertain. This study evaluated the efficacy and safety of CEPD during TAVR using trial sequential analysis (TSA) and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. METHODS: Randomized controlled trials (RCTs) comparing TAVR with and without CEPD were identified through four electronic databases from inception to April 2025. Primary outcomes were all-cause mortality, major adverse cardiovascular and cerebrovascular events (MACCE), stroke, and disabling stroke. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated. TSA was conducted with a 5% type I error and 80% power. RESULTS: Nine RCTs including 11,876 patients were analyzed. CEPD use showed no significant reduction in mortality, MACCE, stroke, or disabling stroke. Secondary and subgroup analyses yielded consistent findings. TSA demonstrated that the accrued evidence was insufficient to confirm a clinical benefit. CONCLUSIONS: Current evidence does not support the routine use of CEPD during TAVR, given the lack of significant benefit in key clinical outcomes. REGISTRATION: The protocol of this study was registered at Prospero CRD420251036308.
Elazab et al. (2026) conducted a meta-analysis in Severe aortic stenosis undergoing TAVR (n=11,876). Cerebral embolic protection devices (CEPD) vs. TAVR without CEPD was evaluated on All-cause mortality, major adverse cardiovascular and cerebrovascular events (MACCE), stroke, and disabling stroke. Cerebral embolic protection devices during TAVR showed no significant reduction in mortality, MACCE, stroke, or disabling stroke compared to TAVR without protection.
Synapse has enriched 10 related papers. Consider them for comparative context: